1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,300 | 1,410 | 21.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Tevogen Bio Inc: Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned | 65 | GlobeNewswire (Europe) | 600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU.Current ownership breakdown: Insiders 79%; Independent Board... ► Artikel lesen | |
| Mo | Tevogen Bio CEO reinforces commitment to retention of equity capital | 2 | Seeking Alpha | ||
| 15.02. | Tevogen Bio Inc: Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision | 102 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy... ► Artikel lesen | |
| 14.02. | Tevogen Bio Inc: Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency | 59 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of... ► Artikel lesen | |
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 14.02. | Tevogen Bio Inc: Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity | 1 | GlobeNewswire (USA) | ||
| 13.02. | Tevogen Bio Inc: Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans | 1 | GlobeNewswire (USA) | ||
| 11.02. | Tevogen Bio Holdings Inc. (TVGN) Engages BARDA on AI-Driven ExacTcell Immunotherapy Advancements | 1 | Insider Monkey | ||
| 10.02. | Tevogen Bio Inc: Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation | 112 | GlobeNewswire (Europe) | WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma... ► Artikel lesen | |
| 07.02. | Tevogen Bio Inc: Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell Technology's Potential as a Scalable Medical Countermeasure | 1 | GlobeNewswire (USA) | ||
| 29.01. | Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration | 7 | Insider Monkey | ||
| 28.01. | Tevogen Bio Inc: Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding | 75 | GlobeNewswire (Europe) | The grant funding will further Tevogen Bio's mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial... ► Artikel lesen | |
| 28.01. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.01. | Tevogen Bio Inc: Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach | 1 | GlobeNewswire (USA) | ||
| 27.01. | What's Going On With Tevogen Bio Stock Today? | 2 | Benzinga.com | ||
| 27.01. | Tevogen Bio and Microsoft expand AI collaboration to PredicTcell tech | 4 | Pharmaceutical Technology | ||
| 27.01. | Tevogen Bio shares surge on expanded Microsoft collaboration in AI tech development | 9 | Investing.com | ||
| 27.01. | Tevogen Bio-Aktien schnellen nach Ausweitung der Microsoft-Kooperation bei KI-Entwicklung in die Höhe | 6 | Investing.com Deutsch | ||
| 27.01. | Tevogen Bio expands AI partnership with Microsoft | 8 | Seeking Alpha | ||
| 25.01. | Tevogen stock rallies on expanded Microsoft AI collaboration | 10 | Seeking Alpha | ||
| 24.01. | Tevogen Bio Inc: Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure | 225 | GlobeNewswire (Europe) | This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio's proprietary technology, is designed for predictive, precision T cell target identification.... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
79 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,375 | -0,33 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| AMGEN | 291,45 | +0,57 % | Amgen: Biotech-Gigant mit Rücksetzer nach starken Q4-Zahlen! | EMA-20 als Sprungbrett! Rückblick Amgen ist ein führendes Unternehmen auf dem Gebiet der biotechnologisch basierten Humantherapeutika und verfügt über langjährige Erfahrung mit Produkten zur Unterstützung... ► Artikel lesen | |
| NOVAVAX | 7,641 | +0,16 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.02.2025 | The following instruments on Xetra do have their last trading day on 17.02.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 17.02.2025.ISIN NameUS6700024010 Novavax Inc. ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,965 | +1,47 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 673,40 | +0,51 % | Dupixent von Regeneron und Sanofi erhält bevorzuge US-Prüfung | DJ Dupixent von Regeneron und Sanofi erhält bevorzuge US-Prüfung
Von Colin Kellaher
DOW JONES--Der Entzündungshemmer Dupixent von Sanofi und Regeneron Pharmaceuticals könnte bald in einer neuen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,180 | +1,87 % | INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications | Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,041 | +6,58 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,560 | -3,76 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,796 | -0,05 % | JMP Securities maintains BioCryst stock with $18 target | ||
| BIOMARIN PHARMACEUTICAL | 65,90 | +0,98 % | Biomarin Pharmaceutical Aktie: Neuer Auftrieb für die Aktie | Das Biotechnologieunternehmen Biomarin Pharmaceutical verzeichnete im vierten Quartal einen bemerkenswerten Erfolg. Der Nettogewinn stieg deutlich auf 125 Millionen Dollar, was einem Gewinn pro Aktie... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,406 | -1,93 % | NurExone Biologic Inc.: NurExone Biologic setzt die Expansion seiner US-Präsenz und Bekanntheit mit prestigeträchtiger Konferenzpräsentation fort | TORONTO und HAIFA, Israel, 14. Feb. 2025 -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Deutschland: J90) ("NurExone" oder das "Unternehmen") freut sich bekannt zu geben, dass es auf der... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 19,225 | +1,08 % | Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting... ► Artikel lesen | |
| XOMA ROYALTY | 23,200 | +1,75 % | Dividendenbekanntmachungen (03.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGRICULTURAL BANK OF CHINA LTD ADR US00850M1027 0,4001 USD 0,3897 EUR AMERICAN EXPRESS COMPANY US0258161092 0,7 USD 0,6818 EUR AUTO... ► Artikel lesen | |
| IMMUNITYBIO | 3,304 | +0,89 % | ImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - Time to Buy? | ||
| IMMUNIC | 1,237 | +2,57 % | EQS-News: Immunic AG: Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing | Issuer: Immunic AG
/ Key word(s): Study results
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,450 Euro und damit -0,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.
